

Special Issue

Personalized Therapy for Basic and Translational in Upper Gastrointestinal Cancer

Message from the Guest Editor

Upper gastrointestinal cancer, encompassing gastroesophageal, pancreatic and hepatobiliary tract cancer, is one of the most common cancers worldwide, with high morbidity and mortality. In recent years, from the beginning of diagnosis to the development of new surgical techniques to the most innovative medical therapies, the treatment of these tumors has changed profoundly. Furthermore, today's developments in translational oncology allow for personalized treatments based on molecular profiling and genetic tools. Interestingly, an emerging key role of microbiota both in carcinogenesis and treatment response has been highlighted in the last few years.

Evolving strategies for early cancer detection and treatment have improved overall survival. Gastrointestinal cancer surgeries, such as laparoscopy and robotic resection, are still effective treatments. In addition to traditional chemotherapy, targeted therapy and immunotherapy have further improved the treatment and survival rate of patients with upper gastrointestinal cancer, providing new opportunities for personalized cancer treatment.

Guest Editor

Dr. Valeria Merz

1. Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, 37134 Verona, Italy
2. Medical Oncology Unit, Santa Chiara Hospital, 38122 Trento, Italy

Deadline for manuscript submissions

closed (20 February 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/192682

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).